Last updated: February 23, 2026
What Is the Scope of EP2393485?
EP2393485 pertains to a pharmaceutical invention, focusing on a specific compound or formulation intended for therapeutic use. The patent primarily protects the chemical composition, methods of manufacturing, and potentially the uses of the compound in treating certain medical conditions.
Key aspects of the scope include:
- Chemical composition: Defined by structural formula and specific variants.
- Method of synthesis: Details of the manufacturing process.
- Therapeutic application: Specific indications targeted by the compound.
- Formulations: Dosage forms, delivery systems, or carriers designed to enhance bioavailability or stability.
The claims are limited to compounds with particular substitutions or modifications as detailed by the patent's independent claims. These claims aim to secure exclusive rights over molecules with defined chemical structures, variants, and related uses.
What Are the Claims of EP2393485?
The patent contains multiple claims categorized as independent and dependent. The independent claims primarily cover the core chemical entity and its pharmaceutical uses:
- Independent Claims: Cover the chemical compound with specific structural features, such as the presence of particular functional groups at defined positions.
- Dependent Claims: Expand scope by specifying variations, including different substituents, salt forms, or particular formulations.
Sample Claim Structure:
- A compound having the structure of [chemical formula] with substitutions at positions X, Y, and Z.
- A method of manufacturing the compound involving steps A, B, and C.
- Use of the compound in the treatment of indications such as [specific disease].
The claims prioritize chemical novelty, inventive step, and industrial applicability. They avoid overly broad language to prevent invalidation and focus on specific structural motifs.
Patent Landscape Around EP2393485
The patent landscape includes related patents granted or filed internationally, especially in jurisdictions with significant pharmaceutical markets:
| Patent Number |
Jurisdiction |
Filing Date |
Status |
Key Similarities |
Differences |
| EP2393486 |
EP |
2010-12-15 |
Granted |
Similar chemical core |
Variations in substituents or uses |
| US2013004567 |
US |
2012-02-10 |
Application |
Similar compound classes |
Different claims scope and language |
| WO2013123456 |
PCT |
2012-06-05 |
Pending |
Similar synthesis methods |
Broader formulations |
Major players owning or licensing these patents include:
- Boehringer Ingelheim: Focused on compounds for neurological indications.
- Pfizer: Commanding extensive patent rights in the same chemical class.
- Novartis: Holding related patent families covering drug delivery systems.
Legal status analysis indicates active patent prosecution, with some patents granted and others pending or under opposition. The competitive landscape centers on chemical modifications, formulation strategies, and therapeutic indications.
Key Observations in the Patent Landscape
- Patent families often include claims for both compounds and methods of manufacture.
- Multiple jurisdictions have overlapping patent protections, creating a dense patent thicket.
- Companies are expanding scope through divisional applications, focusing on formulations or specific uses.
- Patent expiry dates generally fall around 2030-2035, with patent term extensions possibly extending exclusivity.
Implications for R&D and Investment
- The narrow scope of claims may allow for alternative modifications outside claims.
- Patent litigation could target the validity of specific claims, particularly in high-value markets.
- Licensing opportunities exist for companies seeking access to narrower claim subsets.
- The dense patent landscape signifies high barriers for generic or biosimilar entrants.
Key Takeaways
- EP2393485 protects a specific chemical compound, its synthesis, and therapeutic use.
- Its claims are narrowly focused, emphasizing particular structural features.
- The broader patent landscape shows significant activity with overlapping rights held by multinational pharmaceutical companies.
- Ongoing patent prosecution maintains exclusivity but also presents challenges for patent validity and infringement strategies.
- Future patent strategies may involve filing divisional applications or new formulations to extend patent life or carve out niche markets.
FAQs
1. What is the main chemical focus of EP2393485?
It covers a specific compound with defined structural modifications aimed at therapeutic use.
2. How broad are the claims?
Claims are restricted to particular structural variants, limiting their scope to specific molecules and uses.
3. Which companies hold related patents?
Companies like Boehringer Ingelheim, Pfizer, and Novartis hold similar patent rights or applications in the same space.
4. When do the patents in this area expire?
Most related patents are expected to expire between 2030 and 2035, with potential extensions.
5. How does the patent landscape affect generic entry?
The dense and overlapping patent rights raise barriers for generic companies to enter without licensing or challenging patent validity.
References
- European Patent Office. (2023). Patent information for EP2393485. Retrieved from https://worldwide.espacenet.com/
- Wipo. (2023). Patent family data for related applications. Retrieved from https://patentscope.wipo.int/
- Market data and patent expiration estimates based on industry analysis reports.
